Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP1 | P24666 | 11/20 | 0.50 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.47 |
| ▸ | AHR | P35869 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23015126 | 1.00 | ACP1 (0.50) | ACP1SMARCA2SLC2A1AHR | |
| SCHEMBL29636750 | 0.90 | ACP1 (0.48) | ACP1SMARCA2SLC2A1 | |
| SCHEMBL29636698 | 0.90 | ACP1 (0.53) | ACP1SMARCA2SLC2A1 | |
| SCHEMBL23029697 | 0.86 | ACP1 (0.55) | ACP1SMARCA2SLC2A1 | |
| SCHEMBL16098534 | 0.84 | SLC2A1 (0.65) | ACP1SMARCA2SLC2A1 | |
| SCHEMBL23029700 | 0.83 | SLC2A1 (0.60) | ACP1SLC2A1 | |
| Hydrochloric Acid SCHEMBL16102182 | 0.83 | SLC2A1 (0.67) | ACP1SMARCA2SLC2A1 | |
| Hydrochloric Acid SCHEMBL16097746 | 0.83 | SLC2A1 (0.67) | ACP1SMARCA2SLC2A1 | |
| Hydrochloric Acid SCHEMBL29636760 | 0.83 | SLC2A1 (0.59) | ACP1SLC2A1 | |
| SCHEMBL23029676 | 0.82 | ACP1 (0.51) | ACP1SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4017492-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | Biohaven Therapeutics Ltd. (US) | 2022-06-29 | — | — | EP | claimed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |